Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral pIL-12 Electroporation in Refractory HNSCC
NCT02345330Phase 2Terminated
- Sponsor
- OncoSec Medical
- Start
- May 2015
- Primary completion
- Nov 2016
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of tavokinogene telseplasmid in head and neck squamous cell carcinoma (HNSCC), sponsored by OncoSec Medical. Started May 2015; status: terminated.
02
Drugs
tavokinogene telseplasmid
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02345330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02345330.